tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amplia Therapeutics Reports Promising Interim Results from ACCENT Trial

Story Highlights
Amplia Therapeutics Reports Promising Interim Results from ACCENT Trial

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Amplia Therapeutics ( (AU:ATX) ) just unveiled an update.

Amplia Therapeutics has announced positive interim data from its ACCENT trial, which is evaluating the efficacy of its FAK inhibitor, narmafotinib, in combination with standard chemotherapies for advanced pancreatic cancer. The trial results show significant improvements in progression-free survival and objective response rates compared to chemotherapy alone, indicating a promising advancement in treatment options for pancreatic cancer patients. The company is preparing for a potential pivotal phase 2b/3 trial, which could enhance its position in the oncology market and offer new hope for stakeholders in the healthcare sector.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

More about Amplia Therapeutics

Amplia Therapeutics Limited is a biotechnology company focused on developing innovative treatments for cancer. The company specializes in the development of FAK inhibitors, with its lead product, narmafotinib, being investigated for its efficacy in treating advanced pancreatic cancer.

Average Trading Volume: 7,163,090

Technical Sentiment Signal: Buy

Current Market Cap: A$111.9M

Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1